Te Ahumairangi Investment Management Ltd Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Te Ahumairangi Investment Management Ltd lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,549 shares of the biopharmaceutical company’s stock after selling 1,711 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $3,511,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $1,012,296,000. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Dodge & Cox raised its position in Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after buying an additional 724,562 shares during the last quarter. AQR Capital Management LLC raised its position in Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after buying an additional 606,612 shares during the last quarter. Finally, Invesco Ltd. raised its position in Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after buying an additional 408,649 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of Regeneron Pharmaceuticals stock opened at $611.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $503.25 and a 12-month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $64.65 billion, a PE ratio of 14.90, a price-to-earnings-growth ratio of 1.32 and a beta of 0.25. The company has a 50-day moving average of $695.41 and a two-hundred day moving average of $739.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the company posted $8.22 earnings per share. The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Investor-focused writeups highlighted a bullish thesis on Regeneron, pointing to valuation metrics that look reasonable for a large-cap biotech and reinforcing the view that the stock may be attractive for long-term buyers. Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?
• Positive Sentiment: Regeneron-backed Parabilis Medicines completed a record-setting biotech IPO, and Regeneron also participated in a $75 million private placement, which could be viewed as a strategic investment in an emerging drug developer. Parabilis Medicines, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock at $20.00 per Share
• Neutral Sentiment: Regeneron announced a clinical-study update testing weekly Praluent dosing in a cholesterol trial; investors will likely watch for any sign the program could support future label expansion or demand, but this is still an early-stage study update. Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
• Negative Sentiment: Pomerantz LLP and Schall Law Firm both disclosed investigations into possible claims involving Regeneron, which adds legal overhang and could weigh on sentiment if the probes broaden or lead to litigation. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Sensorion said it is shifting away from a hearing-loss gene therapy partly because the development environment has changed due to Regeneron competition, underscoring that REGN’s pipeline and competitive position can pressure rivals in specific therapeutic areas. Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

Analyst Upgrades and Downgrades

REGN has been the subject of a number of analyst reports. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Canaccord Genuity Group decreased their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.